Citius Oncology reports growing LYMPHIR adoption and market access

Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort

Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial

Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer

Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation

Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas

CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring

Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer

Coiled Therapeutics doses first patient with optimised AO-252 formulation

GlycoNex commences dosing in Phase I trial of GNX1021 in Japan

IMPACT Therapeutics grants Pharmanovia exclusive rights to senaparib across 66 countries

Datroway approved in EU for first-line metastatic triple-negative breast cancer

Karyopharm reports topline Phase 3 trial results in endometrial cancer

Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten

10x Genomics and Lausanne University Hospital to collaborate on cancer care research